Sign in
KAPA Stock Price, Chart, Stats & News
Kairos Pharma, Ltd.
Save
Kairos Pharma, Ltd. (KAPA) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
KAPA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -62.76% |
ROE | -79.19% |
D/E | – |
Interest coverage ratio | -41.02x |
KAPA valuation
P/E | – |
P/S | – |
P/B | 1.53x |
P/CF | -2.81x |
P/FCF | -3.62x |
P/OCF | -2.81x |
PEG | -0.25x |
EV multiple | -3.69x |
About
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016.
Similar securities
Based on sector and market capitalization
Report issue